Matches in DBpedia 2016-04 for { <http://citation.dbpedia.org/hash/cb3283123e232f990c549407f65d39f3cd20f3279d7e838ad7911873482bc154> ?p ?o }
Showing triples 1 to 8 of
8
with 100 triples per page.
- cb3283123e232f990c549407f65d39f3cd20f3279d7e838ad7911873482bc154 displayAuthors "etal".
- cb3283123e232f990c549407f65d39f3cd20f3279d7e838ad7911873482bc154 first "C, L, S".
- cb3283123e232f990c549407f65d39f3cd20f3279d7e838ad7911873482bc154 isCitedBy Eculizumab.
- cb3283123e232f990c549407f65d39f3cd20f3279d7e838ad7911873482bc154 journal "Presented at: American Society of Nephrological Kidney Week 2012".
- cb3283123e232f990c549407f65d39f3cd20f3279d7e838ad7911873482bc154 last "Legendre, Greenbaum, Babu".
- cb3283123e232f990c549407f65d39f3cd20f3279d7e838ad7911873482bc154 location "San Diego, CA".
- cb3283123e232f990c549407f65d39f3cd20f3279d7e838ad7911873482bc154 quote "--10-30".
- cb3283123e232f990c549407f65d39f3cd20f3279d7e838ad7911873482bc154 title "Eculizumab is atypical hemolytic uremic syndrome patients with progressing TMA: continued improvements at 2-year follow-up".